---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-033247"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:07:38.760437+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioXcel Q4 net loss narrows to $22.3M; cash runs only to mid-2024; FDA requires more TRANQUILITY data

## Summary
- Net loss $22.3M Q4 2023 vs $54.8M Q4 2022; full-year net loss $179.0M vs $165.8M.
- Cash and equivalents $65.2M at Dec 31, 2023, expected to fund operations only through mid-2024.
- FDA requires additional Phase 3 efficacy/safety data for BXCL501 in care facilities for Alzheimer's agitation (TRANQUILITY); at-home trial re-evaluated.
- SERENITY program: FDA meeting supports Phase 3 trial amendment for at-home use of 120 mcg BXCL501 for bipolar/schizophrenia agitation.
- Initiated formal process to assess strategic options for OnkosXcel Therapeutics subsidiary.

## SEC filing metadata
- accession: 0001104659-24-033247
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465924033247/0001104659-24-033247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465924033247/tm248359d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-033247
- JSON: https://secwatch.observer/filing/0001104659-24-033247.json
- Plain text: https://secwatch.observer/filing/0001104659-24-033247.txt

## Key facts
- Earnings Releases
  BioXcel Therapeutics, Inc. reported the fourth quarter and full year 2023 results: revenue Net revenue from IGALMI was $376,000 for the fourth quarter of 2023.
  - Period: the fourth quarter and full year 2023
  - Revenue: Net revenue from IGALMI was $376,000 for the fourth quarter of 2023
  - Result: reported results
  source text: Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465924033247/0001104659-24-033247-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.